PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Skin biopsy test detects abnormalities of key biomarker in neurodegenerative disorders

Estimated to affect 2.5 million people in the US, synucleinopathies comprise four neurodegenerative disorders.

Neurologists from the Beth Israel Deaconess Medical Center (BIDMC) have revealed that a simple skin biopsy test could detect abnormal amounts of alpha-synuclein, a key biomarker of Parkinson’s disease (PD), as well as other neurodegenerative disorders.

Published in the Journal of American Medical Association and sponsored by the National Institute of Health, the results of the study could help physicians make more accurate diagnoses and improve clinical trials for alpha-synuclein targeting investigational drugs.

Affecting an estimated 2.5 million people in the US, synucleinopathies comprise four neurodegenerative disorders: PD, dementia with Lewy bodies (DLB), multiple system atrophy (MSA) and pure autonomic failure (PAF), which share a common pathologic lesion called phosphorylated alpha-synuclein (P-SYN).

Building on a previous BIDMC study in 2023, which demonstrated that skin biopsies could distinguish between PD and MSA, which both have similar prognoses, the Synuclein-One Study enrolled 428 people aged 40 to 99 years old, with a clinical diagnosis of one of the four synucleinopathies with no previous history of neurodegenerative disease who underwent three 3mm skin punch biopsies taken from the neck, knee and ankle.

Results found that 93% of PD patients demonstrated a positive skin biopsy for P-SYN, while those with DLB and MSA tested 96% and 98% positive, respectively.

Additionally, 100% of patients with PAF were positive for P-SYN, while just over 3% of those in the control group tested positive for the abnormal protein.

Researchers hope that the findings from the study will help accelerate drug development for synucleinopathies.

Christopher Gibbons, neurologist at BIDMC and professor of neurology at Harvard Medical School (HMS), said: “This… study demonstrated how we can more objectively identify the underlying pathology of synucleinopathies and offer better diagnostic answers.”

Roy Freeman, director, BIDMC’s Center for Autonomic and Peripheral Nerve Disorders and professor of neurology at HMS, said: “Identifying the relevant biomarker… and tracking it over the course of a clinical trial is an essential component of drug development in the neurodegeneration field.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026